Henry Schein, Inc. (HSIC), based in Melville, New York, is a global leader in healthcare product distribution, serving the ...

Henry Schein, Inc. (HSIC) stock saw a modest uptick, ending the day at $73.22 which represents a slight increase of $1.47 or 2.05% from the prior close of $71.75. The stock opened at $72.23 and ...

With the game of the season just days away, WIVB News 4 Sports Director Josh Reed recently spoke with SiriusXM’s Adam Schein ...

The Acentus transaction follows Henry Schein’s acquisition of Prism Medical Products, LLC in 2021 and Shield Healthcare and ...

Evercore ISI analyst Elizabeth Anderson CFA maintained a Hold rating on Henry Schein (HSIC – Research Report) yesterday and set a price target ...

This was the stock's second consecutive day of losses.

Shares of Henry Schein, Inc. (NASDAQ:HSIC – Get Free Report) have been assigned an average recommendation of “Moderate Buy” ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Provident Healthcare Partners ("Provident"), a leading healthcare investment banking firm, announced it has advised Acentus ...

NAW said Henry Schein’s CEO won the award for his leadership, service and engagement with the association and distribution ...

The projected fair value for Henry Schein is US$67.04 based on 2 Stage Free Cash Flow to Equity With US$70.70 share price, Henry Schein appears to be trading close to its estimated fair value ...

Tampa, Florida-based Acentus, a national medical supplier, specializes in the delivery of continuous glucose monitors (CGMs).